BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Curing Atopic Dermatits in Children With a Commerical Medical Device and Maintaining Healthy Skin by Using a New Cosmetic Product
Not Applicable
Completed
- Conditions
- Dermatitis, Atopic
- Interventions
- Other: Stelatopia (cosmetic comparator)
- First Posted Date
- 2015-11-26
- Last Posted Date
- 2017-09-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 136
- Registration Number
- NCT02615561
Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept
Completed
- Conditions
- Macular Degeneration
- Interventions
- Behavioral: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- First Posted Date
- 2015-11-26
- Last Posted Date
- 2017-09-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 716
- Registration Number
- NCT02615496
Burden of Illness in Atrial Fibrillation
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- Drug: Standard of care in AF in Denmark
- First Posted Date
- 2015-11-26
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 107532
- Registration Number
- NCT02615587
Atrial Fibrillation Patient Preference Study
Completed
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 382
- Registration Number
- NCT02611635
Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
Phase 2
Completed
- Conditions
- Mesothelioma
- Interventions
- Drug: Anetumab ravtansine (BAY94-9343)Drug: Vinorelbine
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2020-11-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 248
- Registration Number
- NCT02610140
Subtherapeutic INR Levels in Patients With AVK: Incidence, Associated Factors, Prognosis and Control Strategies
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1013
- Registration Number
- NCT02610153
Anticoagulation Preference by AF Patients Study
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- Other: VKAsOther: NOACs including Rivaroxaban (Xarelto, BAY59-7939)Other: EdoxabanOther: ApixabanOther: Dabigatran-etexilate
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2017-09-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 198
- Registration Number
- NCT02607371
Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2016-11-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 36
- Registration Number
- NCT02606864
Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma
Phase 1
Withdrawn
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2015-11-16
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Bayer
- Registration Number
- NCT02605356
To Assess Bioequivalence of Loratadine Oral Solution/Syrup Versus Claritin Peach Syrup
Phase 1
Completed
- Conditions
- Histamine H1 Antagonists, Non-Sedating
- Interventions
- First Posted Date
- 2015-11-01
- Last Posted Date
- 2017-02-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 54
- Registration Number
- NCT02593747
© Copyright 2025. All Rights Reserved by MedPath